BMRN vs. JAZZ

In the year-to-date period, BMRN achieves a -3.70% return, which is significantly higher than JAZZ's -10.03% return. Over the past 10 years, BMRN has underperformed JAZZ with an annualized return of -5.86%, while JAZZ has yielded a comparatively higher -4.89% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Jazz Pharmaceuticals plc (JAZZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMRN Sharpe Ratio is -0.87, which is lower than the JAZZ Sharpe Ratio of 0.03. The chart below compares the historical Sharpe Ratios of BMRN and JAZZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BMRN nor JAZZ has paid dividends to shareholders.

The maximum BMRN drawdown since its inception was -90.58%, smaller than the maximum JAZZ drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for BMRN and JAZZ. For additional features, visit the drawdowns tool.

BioMarin Pharmaceutical Inc. (BMRN) and Jazz Pharmaceuticals plc (JAZZ) have volatilities of 17.90% and 17.53%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.